The REDUCE-AMI trial found that long-term beta-blocker therapy does not reduce mortality risk in acute myocardial infarction patients with preserved left ventricular ejection fraction compared to no beta-blocker treatment.
MSD mulls 2025/26 launch for RSV vaccine after Phase II/III win
Clesrovimab is a single dose extended half-life monoclonal antibody developed as a passive immunisation for the prevention of RSV. Image credit: Sergiy Palamarchuk / Shutterstock.